FINANCINGS
Amicus Therapeutics Inc. closed a public offering with gross proceeds expected to total $258.8 million.
Arca Biopharma Inc. closed its private placement financing for net proceeds of about $34 million.
Axovant Sciences Ltd. completed its IPO for gross proceeds of about $362 million.
Catabasis Pharmaceuticals Inc. set terms for its IPO, planning to raise approximately $60 million.
Cynapsus Therapeutics Inc. priced a public offering for total gross proceeds of about $63 million.
Cytomx Inc. has raised $70 million from a series D financing.
Heron Therapeutics Inc. closed its public offering of about 5.5 million shares of common stock, which grossed $136.6 million.
Kezar Life Sciences completed a series A financing totaling $23 million.
Luqa Pharmaceuticals raised $15 million from a series A financing.
Milestone Pharmaceuticals Inc. closed a $17 million series B financing round.
Ocata Therapeutics Inc. priced an underwritten offering, with gross proceeds expected to be $30.25 million.
Seres Therapeutics Inc. set terms for a $100 million IPO, planning to sell about 6.3 million shares between $15 and $17 each.
DEALS
Adimab LLC said it established a new collaboration with Kite Pharma Inc. to identify fully human antibodies against selected targets.
Agalimmune Ltd. licensed Kode Biotech Ltd.’s function-spacer-lipid cell surface membrane modification technology to incorporate it into its cancer immunotherapy molecules.
Allergan plc is acquiring Kythera Biopharmaceuticals Inc. in a cash-and-shares deal worth about $2.1 billion.
Atara Biotherapeutics Inc. exercised its option with Memorial Sloan Kettering Cancer Center to license certain clinical-stage, allogeneic T-cell therapies for various cancers and viral infections.
Avexis Inc. is licensing Asklepios Biopharmaceutical Inc.’s Duplex vectors technology for use in its phase I AAV gene transfer trial in spinal muscular atrophy patients.
Bayer Healthcare and Johns Hopkins University entered an agreement to jointly develop new ophthalmic therapies targeting retinal diseases.
Bionaturis Group SA and Biological Mimetics Inc. are jointly developing vaccines for human and animal health applications.
Plasmatech Biopharmaceuticals Inc. licensed an AAV gene therapy and IP from the University of Minnesota to treat patients with Fanconi anemia.
Teva Pharmaceutical Industries Ltd. is partnering with Microchips Biotech Inc. to develop a tiny implantable chip capable of storing and releasing hundreds of therapeutic doses of drug.
. . . AND MORE
Check out BioWorld Today’s extensive coverage of the BIO 2015 International Convention.
Actavis plc adopted Allergan plc as its new global name and began trading under a new symbol, AGN, on the New York Stock Exchange.
Corbus Pharmaceuticals Holdings Inc. received FDA orphan drug designation for its lead candidate, Resunab, to treat systemic sclerosis.
Juventas Therapeutics Inc. said JVS-100 received fast track designation from the FDA for the treatment of advanced ischemic chronic heart failure.
Nutrinia Ltd. said the FDA granted orphan drug designation for its orally administered drug for treating short bowel syndrome.
The Biotechnology Industry Organization will become known as the Biotechnology Innovation Organization, with the change taking effect by the beginning of 2016.
Verona Pharma plc said it has undertaken a secondary listing on the Xetra exchange, part of the Deutsche Borse in Germany.